SPONSOR
Second Affiliated Hospital of Guangzhou Medical University
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 2, Phase 3
Conditions studied: Hepatocellular CarcinomaLiver CancerAntibodyHepatocellular Carcinoma Non-resectableLung CancerSolid Tumor, Adult
NCT05992584 Phase 2
Recruiting
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Hepatocellular Carcinoma
NCT06482801 Phase 2
Recruiting
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Liver Cancer
NCT06397222 Phase 2
Recruiting
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Hepatocellular Carcinoma Non-resectable
NCT06478108 Phase 2, Phase 3
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
Lung Cancer